IP Library Patent Application 13851720
Patent Application
App. No. 13/851,720

Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/851,720
Abstract

The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.

Claims (14)

1 .- 20 . (canceled)

21 . A method to drive DHA (docosahexaenoic acid)/EPA (eicosapentaenoic acid) incorporation into host tissues using a strain producing conjugated linoleic acid (CLA) comprising administering the strain producing CLA to a subject.

22 .- 25 . (canceled)

26 . The method of claim 21 , wherein the CLA-producing strain is selected from one or more of propionibacteria, lactobacilli, lactococci, streptococci, or bifidobacteria.

27 . The method of claim 26 , wherein the CLA-producing bacterium is selected from one or more of the group of Bif. Breve, Bif. Lactis, Bif. Dentum, Lactobacillus rhamnosus or Butyrivibrio fibrisolvens.

28 . The method of claim 27 , wherein the CLA-producing bacterium is one or more of Bifidobacterium breve as deposited at the National Culture of Industrial and Marine Bacteria under the accession nos. 702258, B. breve DPC 6330 as deposited at the National Culture of Industrial and Marine Bacteria under the accession no, 41497 on 28 Sep. 2007, or B. longum DPC 6315 as deposited at the National Culture of Industrial and Marine Bacteria under the accession no. 41508 on 18 Oct. 2007.

29 . The method of claim 21 , further comprising administration of dietary CLA, alpha-linolenic acid or linoleic acid to the subject.

30 . The method of claim 21 , wherein the subject is a human.

31 . The method of claim 29 , wherein the subject is a human.

32 . The method of claim 21 , wherein the DHA/EPA incorporation improves memory loss and cognition in the subject.

33 . The method of claim 21 , wherein the DHA/EPA reduces inflammation in the subject.

34 . Bifidobacterium breve as deposited at the National Culture of Industrial and Marine Bacteria under the accession nos, 702258.

35 . Bifidobacterium breve DPC 6330 as deposited at the National Culture of Industrial and Marine Bacteria under the accession no. 41497 on 28 Sep. 2007.

36 . Bifidobacterium longurn DPC 6315 as deposited at the National Culture of Industrial and Marine Bacteria under the accession no. 41508 on 18 Oct. 2007.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2021
From: O'MAHONY, LIAM; SHANAHAN, FERGUS; QUIGLEY, EAMONN; ROSS, PAUL; STANTON, CATHERINE
To: UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK; TEAGASC - THE AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY; ALIMENTARY HEALTH LTD.
Reel/Frame 054959/0139 →
CHANGE OF NAME Recorded Jan 19, 2021
From: ALIMENTARY HEALTH LIMITED
To: PRECISIONBIOTICS GROUP LIMITED
Reel/Frame 054959/0144 →